<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352259</url>
  </required_header>
  <id_info>
    <org_study_id>03-Z/KESOPKR-28</org_study_id>
    <nct_id>NCT02352259</nct_id>
  </id_info>
  <brief_title>Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II</brief_title>
  <official_title>Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Maribor</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is prospective, phase II study, The primary objective of the study is evaluation of&#xD;
      the feasibility and safety of intraoperative electrochemotherapy of colorectal liver&#xD;
      metastases. The secondary objective is to determine the efficacy of electrochemotherapy&#xD;
      treatment, based on histological and radiological evaluation of treated metastases. The&#xD;
      endpoints are: toxicity according to the Common Terminology Criteria for Adverse Events&#xD;
      (CTCAE) ver. 4.0 and response rate measured by percentage of vital tumor cells and mRECIST&#xD;
      criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an extension of previously concluded and published study on electrochemotherapy&#xD;
      of colorectal liver metastases (Edhemovic et al. JSO 2014). In this extension 15 patients&#xD;
      will be included. Four groups of patients will be included. The patients from groups 1 and 2&#xD;
      are patients with up to 3 unresectable liver metastases, demanding too excessive resection,&#xD;
      or untreatable by standard thermal ablative methods due to the close proximity of major blood&#xD;
      vessels. Electrochemotherapy will be offered to these patients as the only treatment option.&#xD;
      In case of multiple, both resectable and non-resectable liver metastases, the latter will be&#xD;
      treated with electrochemotherapy, whereas other metastases will be resected or treated by&#xD;
      RFA. These groups of patients are:&#xD;
&#xD;
        1. Patients with one to three (1-3) metachronous liver metastases of colorectal cancer, not&#xD;
           larger than 5 cm, that are positioned in unresectable liver area, near blood vessels,&#xD;
           but in otherwise operable patients.&#xD;
&#xD;
        2. Recurrent liver metastases of colorectal cancer, not more than 3 and not larger than 5&#xD;
           cm in diameter, each. For those patients any other treatment could represent&#xD;
           unacceptable risk due to possibility of insufficient liver residual after resection or&#xD;
           less effective radiofrequency ablation due to the proximity of blood vessels.&#xD;
&#xD;
           Groups 3 and 4 include patients with intent to cure within standard of care using&#xD;
           two-stage surgical approach. This two-stage surgical approach will allow adding&#xD;
           electrochemotherapy during the first operation and tissue collection for histological&#xD;
           analysis during the second operation. Adding electrochemotherapy to these patients will&#xD;
           not affect their treatment within standard of care recommended in the current&#xD;
           guidelines. These groups of patients are:&#xD;
&#xD;
        3. Patients with synchronous metastases, but their general condition and extent of the&#xD;
           disease will not allow simultaneous removal of the primary tumor and metastases. During&#xD;
           the first operation, the primary tumor will be removed (colorectal resection) and some&#xD;
           of the liver metastases will be treated by electrochemotherapy. About 6 weeks later,&#xD;
           during the second operation for liver metastases, both treated and non-treated&#xD;
           metastases will be removed with liver resection.&#xD;
&#xD;
        4. Patients with bilateral, multiple, metachronous metastases in whom standard treatment&#xD;
           includ two-stage liver resection, due to the extent of the disease and/or their general&#xD;
           condition. During the first operation, right portal vein will be ligated and metastases&#xD;
           on the left side will be excised or ablated with radiofrequency ablation. At the same&#xD;
           time, up to three metastases on the right side were treated with electrochemotherapy.&#xD;
           During the second operation, both treated and non-treated metastases on the right side&#xD;
           will be removed with right hemihepatectomy.&#xD;
&#xD;
      Electrochemotherapy will be offered to the patients also when they refuse standard treatment.&#xD;
&#xD;
      Depending on the position of metastases, appropriate electrodes will be selected; hexagonal&#xD;
      needle electrodes with fixed geometry for metastases not larger than 3 cm in diameter, where&#xD;
      their lower edge is located up to 3 cm below the liver capsule. ECT will be performed based&#xD;
      on standard operating procedures for treatment of cutaneous and subcutaneous tumors /&#xD;
      metastases with ECT.&#xD;
&#xD;
      Individual electrodes, positioned according to the prepared treatment plan will be used for&#xD;
      metastases up to 5 cm in diameter, or located near vena cava or large hepatic or portal&#xD;
      veins.&#xD;
&#xD;
      Electrochemotherapy will be performed within 8-28 min after intravenous in bolus&#xD;
      administration of bleomycin (15 mg/m2).&#xD;
&#xD;
      Triggering of electric pulses will be synchronized with ECG signals, through the ECG&#xD;
      triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart.&#xD;
&#xD;
      All patients will be treated after the procedure has been thoroughly described to them, and&#xD;
      have signed informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Safety Related to Electrochemotherapy</measure>
    <time_frame>After operation on day 7</time_frame>
    <description>Recording of adverse events according to CTCAE criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to Treatment (Determined by Modified RECIST Criteria).</measure>
    <time_frame>After operation on the days 30, 60, 90 and 120</time_frame>
    <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI/CT:&#xD;
Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Electrochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrochemotherapy</intervention_name>
    <description>Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.</description>
    <arm_group_label>Electrochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cliniporator Vitae®</intervention_name>
    <description>Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.</description>
    <arm_group_label>Electrochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin PHC 15 e. (United States Pharmacopeia - USP)</intervention_name>
    <description>Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses</description>
    <arm_group_label>Electrochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically and/or cytologically confirmed colorectal cancer.&#xD;
&#xD;
          2. Age over 18.&#xD;
&#xD;
          3. Life expectancy more than 3 month.&#xD;
&#xD;
          4. Performance status Karnofsky ≥ 70 or (World Health Organization) WHO ≤ 2.&#xD;
&#xD;
          5. Chemotherapy free interval 2-5 weeks, depending on the drugs used.&#xD;
&#xD;
          6. Patient must be mentally capable of understanding the information given.&#xD;
&#xD;
          7. Patient must give informed consent.&#xD;
&#xD;
          8. Patient must be discussed at the multidisciplinary team for tumors of the&#xD;
             gastrointestinal tract before entering the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary primary tumor, except surgically treated noninvasive cancer of cervix, or&#xD;
             surgically or irradiated basal cell carcinoma&#xD;
&#xD;
          2. Visceral, bone or diffuse metastases.&#xD;
&#xD;
          3. Life-threatening infection and/or heart failure and/or liver failure and/or other&#xD;
             severe systemic pathologies.&#xD;
&#xD;
          4. Clinically significant ascites.&#xD;
&#xD;
          5. Significant reduction in respiratory function.&#xD;
&#xD;
          6. Age less than 18 years.&#xD;
&#xD;
          7. Coagulation disturbances.&#xD;
&#xD;
          8. Cumulative dose of 250 mg/m2 bleomycin received.&#xD;
&#xD;
          9. Allergic reaction to bleomycin.&#xD;
&#xD;
         10. Impaired kidney function (creatinin &gt; 150 µmol/l).&#xD;
&#xD;
         11. Patients with epilepsy.&#xD;
&#xD;
         12. Patients with arrhythmias.&#xD;
&#xD;
         13. Patients with pacemaker or defibrillator.&#xD;
&#xD;
         14. Pregnancy.&#xD;
&#xD;
         15. Patient incapable of understanding the aim of the study or disagree with the entering&#xD;
             into the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregor Sersa, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Oncology Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Edhemovic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Oncology Ljubljana, Department of Surgical Oncology, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Electrical Engineering, University of Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana, Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Maribor, Maribor, Slovenia</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, Jarm T, Kos B, Pavliha D, Grcar Kuzmanov B, Cemazar M, Snoj M, Miklavcic D, Gadzijev EM, Sersa G. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol. 2014 Sep;110(3):320-7. doi: 10.1002/jso.23625. Epub 2014 Apr 30.</citation>
    <PMID>24782355</PMID>
  </reference>
  <reference>
    <citation>Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, Mali B, Jarm T, Pavliha D, Marcan M, Gasljevic G, Gorjup V, Music M, Vavpotic TP, Cemazar M, Snoj M, Sersa G. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat. 2011 Oct;10(5):475-85.</citation>
    <PMID>21895032</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <results_first_submitted>November 12, 2020</results_first_submitted>
  <results_first_submitted_qc>March 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2021</results_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver metastases of colorectal cancer Electrochemotherapy</keyword>
  <keyword>Bleomycin</keyword>
  <keyword>Electrochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 30, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02352259/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02352259/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Electrochemotherapy</title>
          <description>All patients were administered with intravenous bolus of bleomycin (15,000 IU/m2, Bleomycin medac, Medac, Hamburg, Germany), after intraoperative ultrasound confirmed the correct electrode placement. Eight minutes after bleomycin injection, electric pulses were delivered by Cliniporator®VITAE (IGEA SpA, Carpi, Italy).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Electrochemotherapy</title>
          <description>All patients were administered with intravenous bolus of bleomycin (15,000 IU/m2, Bleomycin medac, Medac, Hamburg, Germany), after intraoperative ultrasound confirmed the correct electrode placement. Eight minutes after bleomycin injection, electric pulses were delivered by Cliniporator®VITAE (IGEA SpA, Carpi, Italy).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRC liver metastases</title>
          <description>Patients presented with CRC liver metastases</description>
          <units>metastases</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Safety Related to Electrochemotherapy</title>
        <description>Recording of adverse events according to CTCAE criteria</description>
        <time_frame>After operation on day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Electrochemotherapy</title>
            <description>All patients were administered with intravenous bolus of bleomycin (15,000 IU/m2, Bleomycin medac, Medac, Hamburg, Germany), after intraoperative ultrasound confirmed the correct electrode placement. Eight minutes after bleomycin injection, electric pulses were delivered by Cliniporator®VITAE (IGEA SpA, Carpi, Italy).</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety Related to Electrochemotherapy</title>
          <description>Recording of adverse events according to CTCAE criteria</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECT nonrelated mild adverse avents</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECT related mild adverse avents</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adverse avents</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Treatment (Determined by Modified RECIST Criteria).</title>
        <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI/CT:&#xD;
Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>After operation on the days 30, 60, 90 and 120</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Electrochemotherapy</title>
            <description>All patients were administered with intravenous bolus of bleomycin (15,000 IU/m2, Bleomycin medac, Medac, Hamburg, Germany), after intraoperative ultrasound confirmed the correct electrode placement. Eight minutes after bleomycin injection, electric pulses were delivered by Cliniporator®VITAE (IGEA SpA, Carpi, Italy).</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Treatment (Determined by Modified RECIST Criteria).</title>
          <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI/CT:&#xD;
Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>complete response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>partial response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>progressive disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7, 30, 60, 90, 120 days</time_frame>
      <desc>adverse events observed in 3 out of 23 patients, no serious adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Electrochemotherapy</title>
          <description>All patients were administered with intravenous bolus of bleomycin (15,000 IU/m2, Bleomycin medac, Medac, Hamburg, Germany), after intraoperative ultrasound confirmed the correct electrode placement. Eight minutes after bleomycin injection, electric pulses were delivered by Cliniporator®VITAE (IGEA SpA, Carpi, Italy).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arrhythmia</sub_title>
                <description>arrhythmia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SIRS</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Systemic inflammatory response syndrome</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Gregor Serša</name_or_title>
      <organization>Institute of Oncology Ljubljana</organization>
      <phone>+38615874343</phone>
      <email>gsersa@onko-i.si</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

